Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: February 5, 2024
Event: Entry into a Material Definitive Agreement regarding the amendment of an existing loan facility.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial data point disclosed is:
- Debt Prepayment: The Company is permitted to make a partial prepayment of loan principal in the amount of $175,000,000 upon the consummation of a separate transaction with Sandoz Inc.
Material Changes
On February 5, 2024, the Company entered into a Consent, Partial Release and Third Amendment to its Loan Agreement with Biopharma Credit PLC and related lenders. Key changes include:
- Asset and Subsidiary Release: Lenders consented to the release of certain assets and subsidiaries from obligations under the Existing Loan Agreement to facilitate a Purchase and Sale Agreement with Sandoz Inc. dated January 19, 2024.
- Covenant Adjustment: The minimum net sales covenant level under the Existing Loan Agreement was adjusted.
- Prepayment Authorization: The amendment permits the $175 million partial prepayment of outstanding loan principal.
Outlook, Risks, and Management Commentary
Management Commentary: The amendment was executed to enable the Company to consummate the asset sale to Sandoz Inc. and manage its debt obligations accordingly. Other terms of the Existing Loan Agreement remain generally identical to the prior version.
Risks and Contingencies: The ability to execute the $175 million prepayment is subject to the consummation of the transactions contemplated by the Purchase Agreement with Sandoz Inc. The filing notes that certain confidential portions of the amendment have been redacted.
Investor Verification Checklist
- Verify the status and expected closing date of the Purchase and Sale Agreement with Sandoz Inc. to confirm the $175 million prepayment will occur.
- Review the specific details of the adjusted minimum net sales covenant in the full text of the Consent and Amendment (Exhibit 10.1).
- Confirm which specific assets and subsidiaries were released from the loan agreement obligations.
- Check subsequent filings for the actual execution of the prepayment and any impact on the Company's remaining debt balance.